Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 799

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 799
---
 ​ | ​ | ​                | ​ |        ​ | ​ | ​ |
| Preferred stock; $0.001 par value; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022, zero shares issued and outstanding at December 31, 2023 and December 31, 2022                                   | ​ | ​ | ​                | ​ |        — | ​ | ​ | ​ | ​                | ​ |        — | ​ | ​ |
| Common stock; $0.001 par value; 8,333,333 shares authorized atDecember 31, 2023 and December 31, 2022, 4,540,059 shares and 4,483,112shares issued and outstanding at December 31, 2023 and December 31,2022, respectively | ​ | ​ | ​                | ​ |        5 | ​ | ​ | ​ | ​                | ​ |        4 | ​ | ​ |
| Additional paid-in capital                                                                                                                                                                                                 | ​ | ​ | ​                | ​ |  742,085 | ​ | ​ | ​ | ​                | ​ |  726,679 | ​ | ​ |
| Accumulated deficit                                                                                                                                                                                                        | ​ | ​ | ​                | ​ | -684,745 | ​ | ​ | ​ | ​                | ​ | -566,232 | ​ | ​ |
| Accumulated other comprehensive loss                                                                                                                                                                                       | ​ | ​ | ​                | ​ |     -260 | ​ | ​ | ​ | ​                | ​ |   -1,672 | ​ | ​ |
| Total stockholders’ equity                                                                                                                                                                                                 | ​ | ​ | ​                | ​ |   57,085 | ​ | ​ | ​ | ​                | ​ |  158,779 | ​ | ​ |
| Total liabilities and stockholders’ equity                                                                                                                                                                                 | ​ | ​ | ​                | $ |  125,844 | ​ | ​ | ​ | ​                | $ |  182,237 | ​ | ​ |

See Notes to Consolidated Financial Statements. F-37

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands, except share and per share data)

| ​                                                                                         
 ​                                                                                         | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |